Chinese Biotech Firms Form Oncology Partnerships
New collaborations focus on refining T-cell engagers and antibody-drug conjugates for improved tumor targeting.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe new biotech collaborations generally lead to safer, more effective cancer treatments?
Henlius and Amberstone Biosciences have entered an $880 million licensing agreement, while Sanyou Biopharmaceuticals and Novocodex Biopharmaceuticals have formed a separate partnership to advance oncology therapies. Both initiatives aim to address limitations in precision and safety for T-cell engagers and antibody-drug conjugates.
Why it matters
These collaborations seek to move beyond existing therapeutic limitations like damage to healthy tissue and payload inconsistency. The shift reflects a growing industry focus on refining how drugs are activated and attached to target cells within solid tumors.
Sanyou has completed more than 800 ADC conjugation projects since establishing its platform in 2020. Amberstone aims to enter the clinic in early 2027 with its lead candidate.
The players
Henlius
A Shanghai-based biopharmaceutical company focused on the development of monoclonal antibodies and oncology treatments.
Amberstone Biosciences
An Irvine, California-based biotech firm specializing in the development of tumor-activated immunotherapy.
Sanyou Biopharmaceuticals
A Shanghai-based research organization that operates a high-throughput platform for antibody and drug discovery.
Novocodex Biopharmaceuticals
A Shaoxing-based company focused on the creation of next-generation antibody-drug conjugates.
Innocare Pharma
A Beijing-based biopharmaceutical company specializing in innovative therapies for cancer and autoimmune diseases.
The details
Amberstone utilizes T-MATE technology, which limits immune-cell activation in healthy tissue by leveraging the distinct acidity of tumor environments. Meanwhile, Novocodex uses site-specific conjugation technology to attach drug payloads to defined locations on antibodies, aiming to solve the payload inconsistency issues found in earlier therapies. These approaches represent attempts to increase the therapeutic window of biologics, which are complex, large-molecule drugs produced by living systems.
Timeline
2020: Sanyou established its antibody-drug conjugate (ADC) discovery platform.
First half of 2027: Amberstone expects its lead T-cell engager to enter the clinic.
The Tech Race
These new deals follow the $3.5 billion Innocare-Lilly collaboration as part of a broader industry trend to secure highly specific, site-directed antibody technologies. The focus remains on surpassing the efficacy of current-generation conjugates, which often suffer from off-target binding.
These developments currently sit in the research and development phase, meaning no products are yet available for clinical use. Oncologists and patients should monitor the 2027 clinical trial entry date as an indicator of whether these technologies can actually reduce patient side effects.
The takeaway
These partnerships signal that the industry is aggressively moving toward acidic-environment activation and site-specific payload conjugation. Stakeholders should watch the 2027 clinical trial milestone to see if these platforms deliver better results than existing standard-of-care therapies.
What happens next
Amberstone Biosciences expects its lead T-MATE T-cell engager to move into clinical trials during the first half of 2027.
Further reading
For broader insights on recent advancements in antibody design, visit the Biotech section.
Source note: This article includes information reported by Bio World.
Live Poll
Do you believe new biotech collaborations generally lead to safer, more effective cancer treatments?
